A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Phase of Trial: Phase III
Latest Information Update: 16 Aug 2017
At a glance
- Drugs Tirasemtiv (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions
- Acronyms VIGOR-ALS
- Sponsors Cytokinetics
- 02 Aug 2017 According to a Cytokinetics media release, the company expects to continue to enroll patients who complete VITALITY-ALS study into VIGOR-ALS throughout 2017.
- 21 Oct 2016 New trial record
- 18 Oct 2016 According to a Cytokinetics media release, first patient has been enrolled in the study.